Company intelligence / Profile preview
Nanjing Pharmaceutical Group
Nanjing, Jiangsu, Chinanjyy.com ↗
- Ownership
- Private
- Employees
- ~4830
- Development stage
- Other
01
Overview
Nanjing Pharmaceutical Group is primarily a pharmaceutical distribution company with commercial products in antiviral influenza medications (flagship product: Paramiavir sodium injection), antibiotics, and cardiovascular drugs. The company also develops generic drugs and modified new drugs, with Phase III clinical trials underway for Paramiavir inhalation solution.[4]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Amphastar Pharmaceuticals (licensing agreement with Nanjing Anji Biotechnology, a separate entity)
Beyond the preview
Go deeper on Nanjing Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Pharmaceutical Group.